Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical announced a capital reduction for Suzhou Angel Fund, a fund in which it holds a 62.50% interest through its subsidiary Ningbo Fuying. The capital reduction, amounting to RMB76.00 million, is a strategic move in light of the upcoming expiry of the fund’s investment period, ensuring alignment with its capital requirements. This transaction, involving connected parties, is subject to Hong Kong Listing Rules but is exempted from certain requirements due to its scale. The equity interests of all partners remain unchanged post-reduction.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products and healthcare services, with a significant market presence in China and international markets.
Average Trading Volume: 7,009,862
Technical Sentiment Signal: Buy
Current Market Cap: HK$68.74B
See more data about 2196 stock on TipRanks’ Stock Analysis page.